Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

20.98USD
28 Apr 2017
Change (% chg)

$-0.01 (-0.05%)
Prev Close
$20.99
Open
$20.91
Day's High
$21.34
Day's Low
$20.64
Volume
74,689
Avg. Vol
125,353
52-wk High
$25.95
52-wk Low
$6.02

Summary

Name Age Since Current Position

Armando Anido

58 2014 Chairman of the Board, Chief Executive Officer

Terri Sebree

2014 President

James Fickenscher

52 2016 Chief Financial Officer, Vice President - Corporate Development

Suzanne Hanlon

58 2014 Vice President - Human Resources, General Counsel, Secretary

Brian Boyd

2017 Vice President - Commercial

Nancy Tich

2016 Vice President - Clinical

Warren Cooper

62 2015 Lead Independent Director

William Federici

56 2015 Director

Thomas Harrison

68 2015 Director

Daniel Kisner

68 2015 Director

Kenneth Moch

61 2015 Director

Cynthia Rask

61 2015 Director

Biographies

Name Description

Armando Anido

Mr. Armando Anido is the Chairman of the Board and Chief Executive Officer of the company. Prior to joining the company, Mr. Anido served as the business consultant from May 2014 to October 2014. He has more than 30 years of executive, operational and commercial leadership experience in the pharmaceutical industry. He served as chief executive officer and as a director of NuPathe, Inc., or NuPathe, a publicly-traded specialty pharmaceutical company, from July 2012 through March 2014, during which time he led the company through FDA approval of its lead product, Zecuity, a transdermal patch for migraines. Prior to joining NuPathe, Mr. Anido served as chief executive officer and president and as a director of Auxilium Pharmaceuticals, Inc., or Auxilium, a specialty pharmaceutical company, from July 2006 through December 2011, where he led the company through FDA approval and commercialization of its lead product, Testim, a testosterone gel. He served as a director of Respira Therapeutics, Inc., a pharmaceutical company, from May 2012 through September 2014 and as a director of Adolor Corporation, a pharmaceutical company, from September 2003 through December 2011. Mr. Anido was retired from January 2012 through June 2012. Mr. Anido holds a B.S. in Pharmacy and an MBA, both from West Virginia University.

Terri Sebree

Ms. Terri B. Sebree is the President of the company. Prior to joining the company, Ms. Sebree served as business consultant from May 2014 to October 2014. She has more than 30 years of executive, development and operational experience in the pharmaceutical industry, particularly in central nervous system product development including epilepsy and pain. Ms. Sebree founded and served as president of NuPathe, a specialty pharmaceutical company, from February 2005 until April 2014, where she led the effort to develop, achieve regulatory approval for and complete manufacturing of the company's lead product, Zecuity, a transdermal patch for migraines. Prior to founding NuPathe, Ms. Sebree served as senior vice president, development of Auxilium, a specialty pharmaceutical company, where she led the development and approval program of Testim, a testosterone gel. Prior to joining Auxilium, she served as executive vice president, U.S. Operations at IBAH, Inc., a contract research organization. Prior to that, she served in a variety of management roles with Abbott Laboratories Inc., a global healthcare company, for over nine years. She currently serves on the board of directors of Serodus ASA, a publicly traded company on the Oslo Stock Exchange. Ms. Sebree holds a B.S. from Texas A&M University.

James Fickenscher

Mr. James E. Fickenscher has been appointed as Chief Financial Officer, Vice President - Corporate Development of the Company, effective September 13, 2016. Mr. Fickenscher joins Zynerba with 28 years of experience in the pharmaceutical industry. Most recently, he was Senior Vice President, Chief Financial Officer at Antares Pharma, a commercial pharmaceutical company focused on self-administered parenteral products. He has also held roles as CFO at Auxilium Pharmaceuticals and Aventis Behring LLC, a wholly owned subsidiary of Aventis, predecessor to Sanofi S.A, as well as business development and strategic planning positions.

Suzanne Hanlon

Ms. Suzanne M. Hanlon is the Secretary, General Counsel and Vice President - Human Resources of the company. Prior to joining the company, Ms. Hanlon served as legal consultant from May 2014 to October 2014. She has more than 25 years of legal experience in the pharmaceutical industry. She served as vice president, associate general counsel of NuPathe from July 2005 to April 2014. Prior to joining NuPathe, Ms. Hanlon served as chief development counsel of Auxilium, a specialty pharmaceutical company. Prior to joining Auxilium, she served as vice president of global contracts and general counsel at IBAH, Inc. Prior to joining IBAH, Inc., She was a partner at Montgomery McCracken Walker & Rhoads LLP. Ms. Hanlon holds a B.A. from Pennsylvania State University and a J.D. from Villanova University School of Law.

Brian Boyd

Mr. Brian Boyd is Vice President - Commercial of the Company. He is a senior pharmaceutical manufacturing executive with more than 30 years of experience driving superior manufacturing process outcomes in the biotechnology and pharmaceutical industries. Most recently, he was Vice President, Process Development for Auxilium Pharmaceuticals and also held senior CMC and manufacturing roles with PolyMedix, Discovery Labs, Aviron/MedImmune Vaccines and US Bioscience/MedImmune. He earned a BS in Chemistry from Denison University.

Nancy Tich

Dr. Nancy Tich, MS, Ph.D, serves as Vice President - Clinical of the Company. Dr. Tich joins Zynerba with more than 26 years of clinical project management experience. Most recently, Dr. Tich served as Senior Director, Project Management, at Covance. She has also held senior clinical roles at Omnicare, Elan Pharmaceuticals and Abbott Laboratories.

Warren Cooper

Dr. Warren D. Cooper M.D. is Lead Independent Director of the Company. Dr. Cooper is a U.K.-trained physician with more than 35 years of experience in the global pharmaceutical industry. He currently serves as the president of Coalescence Inc., a healthcare and pharmaceutical development consultancy, where he has held various positions since 1999. Dr. Cooper was the chief executive officer of Prism Pharmaceuticals, Inc., a venture-backed, specialty pharmaceutical company that he led from inception in September 2004 until the sale of the Company to Baxter International in May 2011. His career in the pharmaceutical industry began with Merck, Sharp and Dohme and spanned 12 years, initially as a clinical research physician in the United Kingdom, then as head of European and, subsequently, Worldwide Clinical Research Operations for Merck Research Laboratories across all therapeutic areas. Moving to AstraMerck (now AstraZeneca PLC) in a broad clinical development role, he eventually led that company's cardiovascular business division, a role with full business lifecycle leadership from in-licensing through development, to P&L responsibility for sales and marketing. Dr. Cooper is a member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. He has previously served on the boards of directors of Nutrition 21, Inc., Nuron Biotech Inc., Cardiorentis AG and the World Affairs Council of Philadelphia. Dr. Cooper studied at the London Hospital where he earned degrees in Physiology (1974) and Medicine and Surgery (1977) granted by the University of London.

William Federici

Mr. William J. Federici is the Director of the Company. He was Director Nominee of the company. Mr. Federici has served as vice president and chief financial officer of West Pharmaceutical Services, Inc., a publicly traded global pharmaceutical technology company, since August 2003. He served as a member of the board of directors at NuPathe and chairman of the Audit committee from January 2011 until February 2014. From June 2002 until August 2003, he was national industry director for Pharmaceuticals of KPMG LLP, and prior thereto, he was an audit partner with Arthur Andersen, LLP. Mr. Federici holds a B.A. in Economics and an M.B.A. in Professional Accounting from Rutgers University and is a Certified Public Accountant.

Thomas Harrison

Dr. Thomas L. Harrison is the Director of the company. Dr. Harrison is a noted author and speaker and since April 2013, has served as chairman emeritus of Diversified Agency Services, the world's largest group of marketing services companies, and a division of Omnicom Group, Inc., or Omnicom. In 1987 he founded Harrison & Star Business Group, a healthcare marketing agency that was acquired by Omnicom in 1992. From 1992 until 1997, he served as chairman of the Harrison & Star Group and chairman of diversified healthcare communications for Omnicom. In 1997, Dr. Harrison was appointed president of diversified agency services, and in 1998 was named chairman and chief executive, serving until 2011. In 1980 he began his agency career at Rolf Werner Rosenthal, a mid-sized healthcare advertising agency. From 1974 until 1980 he served in sales and marketing roles at Pfizer, Inc. Dr. Harrison is a member of the Executive Committee of the Montefiore Hospital, a fellow of the New York Academy of Medicine, and governor of the New York Academy of Sciences where he sits on the Sackler Global Nutrition Committee. In 2013, Dr. Harrison became a partner and board member of Dipexium Pharmaceuticals, Inc. and a board member of rVue Inc., a digital out-of-home media company. In 2014, he was appointed to the boards of Social Growth Technologies, Inc. and of Fifth Street Asset Management Inc. where he serves as chairman of the Audit committee. He previously served as a board member of the New York Chapter of the Arthritis Foundation; a board member for ePocrates, Inc., a publicly traded healthcare information company, until its March 2013 acquisition by athenahealth, Inc.; and The Morgans Hotel Group (2006-2013). Dr. Harrison holds an advanced degree in Cell Biology and Physiology and received an honorary doctorate from West Virginia University in 2007.

Daniel Kisner

Dr. Daniel L. Kisner M.D. is the Director of the company. Dr. Kisner has served as an independent consultant to the pharmaceutical/biotech industry since 2011. From 2003 until 2011 he served as a venture partner/partner at Aberdare Ventures, a venture firm with a focus on investing in healthcare technology companies. Prior to that he was president and chief executive officer of Caliper Technologies Corp., or Caliper, from 1999 until 2003, and served as chairman of Caliper until 2008. He led Caliper from a startup dealing with microfluidic lab-on-a-chip technology to a publically traded commercial company. From 1991 until 1999 He served as chief operating officer and president of Isis Pharmaceuticals, Inc., a biomedical pharmaceutical company. Previously, Dr. Kisner was division vice president of Pharmaceutical Development at Abbott Laboratories and vice president of Clinical Research at SmithKline Beckman Laboratories. In addition he previously held a tenured position at the University of Texas School of Medicine at San Antonio and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Dr. Kisner served on the board of directors of Tekmira Pharmaceuticals from 2010 until March 2015, and he currently serves on the boards of directors of Dynavax Technologies Corporation, Lpath, Inc. and Conatus Pharmaceuticals Inc. He holds a B.A. degree from Rutgers University and an M.D. from Georgetown University.

Kenneth Moch

Mr. Kenneth I. Moch is the Director of the company. Mr. Moch has more than 25 years of experience in managing and financing biomedical technologies, and has played a key role in building five life science companies. He is currently the president of Euclidean Life Science Advisors LLC, where he provides strategic and tactical counsel to the biotechnology and pharmaceutical industries. Prior to that, he served as president and chief executive officer, and as a director, of Chimerix, Inc. from April 2010 to April 2014, having joined the company as chief operating officer in June 2009. Previously, he was president and chief executive officer of three life science companies—BioMedical Enterprises, Inc., Alteon, Inc., and Biocyte Corporation—and was a co-founder and vice president of The Liposome Company, Inc. He also served as managing director of Healthcare Investment Banking at ThinkEquity Partners and as a management consultant with McKinsey & Company. In the public policy arena, Mr. Moch has served as chairman of BioNJ and as a member of the board of the Biotechnology Industry Organization, and is a member of the National Advisory Board of the Johns Hopkins Berman Institute of Bioethics. Mr. Moch received an A.B. in Biochemistry from Princeton University and an M.B.A. with emphasis in Finance and Marketing from the Stanford Graduate School of Business.

Cynthia Rask

Dr. Cynthia A. Rask M.D. is the Director of the company. Dr. Rask has more than 20 years of experience working in the pharmaceutical/biotech industry, seven years of FDA experience, and several years of experience as a clinical neurologist and clinical investigator. Dr. Rask trained in Internal Medicine and Neurology at the University of Rochester and is board-certified in Neurology. Following her residency, she did a fellowship in Epilepsy at the Minnesota Comprehensive Epilepsy Program (MINCEP), and is board certified in Clinical Neurophysiology. She was an assistant professor of Neurology at the University of Minnesota and at Dartmouth College. In 1991, she began her industry career at Abbott Laboratories working on development of a new antiepileptic drug, then joined Genentech Inc. where she led efforts on developing neurotrophic factors for treatment of various types of neuropathic pain. In January of 1999 Dr. Rask began working at the FDA, first as a medical reviewer on INDs and BLAs; in 2002 she was appointed as the division director for the Division of Clinical Evaluation and Pharmacology/Toxicology in the Office of Cellular, Tissue and Gene Therapies (OCTGT). Beginning in 2004, she also served as the acting deputy office director in OCTGT, helping to develop FDA policies and guidance documents and manage the office budget until leaving FDA in June of 2005 to return to the San Francisco Bay area to join a non-profit pharmaceutical company as vice president of Development, an organization funded primarily by grants from the Gates Foundation. In 2006, Dr. Rask began her own consulting company and has worked for a variety of clients including biotech and pharmaceutical companies, ranging in size from small startups to medium and large pharma, academic groups, including Harvard University and the Huntington Study Group, and non-profit organizations, including The Michael J. Fox Foundation. She is a graduate of Cornell University and the University of Minnesota Medical School.